NMIBC Risk Stratification (EAU)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
risk group
—group
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low—
  • Intermediate—
  • High—
  • Very high—
Direct Clinical Answer

The NMIBC Risk Stratification (EAU) calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include tumor number. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

EAU 2021 risk stratification for non-muscle-invasive bladder cancer (NMIBC): low, intermediate, high, or very high risk of recurrence/progression from tumor number, size, prior recurrence rate, T category, concomitant CIS, and grade.

Clinical Indication

The NMIBC Risk Stratification (EAU) is indicated for bedside clinical practice to support EAU 2021 risk stratification for non-muscle-invasive bladder cancer (NMIBC): low, intermediate, high, or very high risk of recurrence/progression from tumor number, size, prior recurrence rate, T category, concomitant CIS, and grade.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.

Limitations & Contraindications

Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.

Clinical Pearls & Action Plan

Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression.

Formula & Variables:

Very high: T1 + high grade + (CIS or multiple/recurrent/large). High: T1 or high grade/G3 or CIS or (multiple AND recurrent AND large Ta low-grade). Low: primary + solitary + Ta + low grade + <3 cm + no CIS. Intermediate: remainder.

Input Parameters

NameTypeRequiredDescription
tumor_numberstringYesNumber of tumors
tumor_sizestringYesLargest tumor diameter
recurrencestringYesPrior recurrence rate
t_categorystringYesT category
cisstringYesConcomitant carcinoma in situ
gradestringYesTumor grade (WHO 2004/2016)

Score Interpretation & Guidance

RangeStageDescription
—LowLow risk NMIBC
—IntermediateIntermediate risk NMIBC
—HighHigh risk NMIBC
—Very highVery high risk NMIBC

Evidence-Based References (EBM)

  • Babjuk M, Burger M, Capitanio U, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Eur Urol. 2022;81(1):75-94.

Related calculators